ABSTRACT
OBJECTIVE： To systematically evaluate the efficacy and safety of febustrin （80 mg/d and 40 mg/d） and allopurinol （300 mg/d） in the treatment of gout， and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from PubMed， Embase， Cochrane library， CJFD， Wanfang database and CBM during from database establishment to Mar. 2019， randomized controlled trial （RCT） about efficacy and safety of febustrin 80 mg/d （trial group）， 40 mg/d （observation group） and allopurinol 300 mg/d （control group） in the treatment of gout were collected. After extracting data of clinical studies met inclusion criteria and quality evaluation with Cochrane system evaluator manual 5.1.0， Meta-analysis was conducted for blood uric acid decrease level， the compliance rate of serum uric acid concentration， incidence of liver dysfunction， incidence of renal dysfunction， incidence of digestive tract reaction and frequency of acute gout attack with Rev Man 5.1 software and Stata 13.0 software. RESULTS： A total of 17 RCTs were included， involving 1 816 patients. Meta-analysis results showed that， the serum uric acid decrease level of patients in trial group [MD＝－70.17， 95％CI （－97.41， －42.93）， P＜0.001] and the compliance rate of serum uric acid concentration [RR＝1.58， 95％CI （1.20， 2.08）， P＝0.001] were higher than observation group； the decrease of serum uric acid level [MD＝－34.68，95％（－61.35， －8.00）， P＝0.01] and the compliance rate of serum uric acid concentration [RR＝1.39，95％CI（1.04，1.85）， P＝0.03] in trial group were significantly higher than control group； the frequency of acute gout attack [RR＝1.54（1.02，2.31）， P＝0.04] in trial group was significantly higher than observation group. The incidence of liver dysfunction in observation group [RR＝0.71，95％CI（0.52，0.99），P＝0.04] was significantly lower than control group， with statistical significance. There was no statistical significance in other indexes among other indexes （P＞0.05）. CONCLUSIONS： Compared with febulostat 40 mg/d and allopurinol 300 mg/d， the efficacy of febulostat 80 mg/d is superior in reducing uric acid levels of gout patients.
ABSTRACT
OBJECTIVE:To evaluate the effectiveness and safety of bromocriptine by vaginal delivery in the treatment of hyperprolactinemia in Chinese female patients,and to provide evidence-based reference for clinic.METHODS:Retrieved from PubMed,The Cochrane Liabmry,Excerpta Medica Database,Chinese Journal Full-text Database,Wanfang Database and China Bxdxiology Medicine disc,randomized controlled trials (RCTs) about bromocriptine oral tablets by vaginal delivery (trial group) vs.bromocriptine by oral administration (control group) in the treatment of bromocriptine in Chinese female patients were collected.After data extraction,quality evaluation of included studies with Cochrane system evaluator manual 5.1.0,Meta-analysis of serum level of Prolactin levels,the rate of menstruation improvement,the rate of pregnancy recovery,the rate of galactorrhea disappearance,the incidence of ADR in digestive tract and the incidence of ADR in nervous system was conducted by using Rev Man 5.1 statistical software.RESULTS:A total of 16 RCTs were included,involving 1 175 patients.The results of Meta-analysis showed that the incidence of ADR in digestive tract [OR=0.14,95％CI(0.09,0.23),P＜0.001] and ADR in nervous system [OR=0.32,95％CI(0.11,0.90),P=0.03] in trial group were significantly lower than control group,with statistical significance.There was no statistical significance in serum level of PRL [MD=0.24,95％ CI (-0.94,1.41),P=0.69],the rate of menstruation improvement [RD=0.04,95％CI (-0.04,0.11),P=0.32],the rate of pregnancy recovery [RD=0.01,95％CI (-0.08,0.10),P=0.84] or the rate of galactorrhea disappearance [RD=0.05,95％ CI (-0.03,0.13),P=0.20] between 2 groups.CONCLUSIONS:Compared with oral administration,bromocriptine by vaginal delivery has no significant difference in therapeutic efficacy but has obvious advantages in the incidence of ADR in digestive tract and in nervous system and better safety.It is suggested to development the special vaginal delivery preparation of bromocriptine.
ABSTRACT
OBJECTIVE:To study the main factors affecting in vitro dissolubility of total puerariae flavones(TPF)bioad?hesive tablets.METHODS:Using HPMC,Carbopol(CP934NP)as bioadhesive and base materials,lactose as porogenic agent to prepare bioadhesive tablets;Basket-rotating method was adopted to determine the dissolubility while0.1mol/L HCl was used as dissolution medium,Rotational speed was100r/min.The accumulated dissolution was detected and the influence of the amount of HPMC,CP,kind of porogenic agent,amount of lactose,size of granules in pressed tablets and medium pH on dissolubility was observed.RESULTS&CONCLUSION:The amount of HPMC,CP and lactose,kind of porogenic agent,size of granules in tablets and medium pH can affect the dissolubility of bioadhesive tablets.
ABSTRACT
OBJECTIVE:To study the dissolution rate of total puerariae flavones(TPF)bioadhesive sustained-release tablet,and to determine its bioadhesive force to animal stomach and small intestine in vitro METHODS:Using rotating basket method,the dissolubility summation was determined with 0 1mol/L HCl as dissolution medium at speed of 100r/min,single-index model,Weibull distributing model,Higuchi equation and zero-class model were used to imitate the dissolution curve The biggest absolute error,the biggest relative error and AIC were used as comprehensive indices to select the best imitating model A new apparatus made by ourselves was used to compare the adhesive force between the sustained-release tablets and popular tablets in adhering to rabbits'stomach or small intestine RESULTS:The results showed that the dissolution rate in vitro imitated in single-index model was the best Bioadhesion study showed that there were obvious differences between bioadhesive sustained-release tablets and non-bioadhesive tablets in adhering with gastric mucosa and small intestines mucosa(P